XP21279 is a prodrug of Levodopa, a dopamine precursor used in the management of Parkinson's disease. XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With...
- Mechanism
- Curator reviewed
XP21279 is a transported prodrug of levodopa,(L-Dopa), a highly effective therapy for the symptoms of Parkinson's disease. XP21279 is designed to engage natural nutrient transport mechanisms located throughout the length of the gastrointestinal, or GI, tract, and then be rapidly converted to L-Dopa by the body's endogenous enzymes. XP21279 is designed to be well absorbed from the lower GI tract,and may be formulated for sustained release, thus reducing fluctuations of L-Dopa levels in the bloodstream. [Xenoport Inc. Website]
- Primary indication
- Investigated for use/treatment in parkinson's disease.Curator reviewed
- Code names
- XP21279
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with XP21279, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account